ClinicalTrials.gg
Not yet recruitingNCT07939165TROCHLEO-CAREUpdated Nov 16, 2026

Trochleoplasty in the Management of Objective Patellar Instability: a Personalized Surgical Approach for the Prevention of Recurrence in Patients With Trochlear Dysplasia

An observational study in Patellar Instability and Trochlear Articular Cartilage Lesions, sponsored by Stefano Zaffagnini. Not yet recruiting at 1 site in Italy. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Stefano Zaffagnini · Observational

How we know

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
152
Ages
14 Years to 50 Years
Sex
All
01

Study summary

This is a multicentre, international, non-profit observational study aimed at prospectively validating a personalized diagnostic and therapeutic algorithm based on the Dejour v3.0 classification in patients with recurrent objective patellar instability and trochlear dysplasia.

The primary objective is to compare treatment failure rates at 24 months between patients with severe trochlear dysplasia (trochlear bump >5 mm) treated with trochleoplasty and MPFL reconstruction, and a retrospective control group with similar trochlear morphology treated without trochleoplasty.

Secondary outcomes include clinical and functional outcomes assessed using validated scores (IKDC, Kujala, Tegner and BPII 2.0), cartilage status assessed by MRI using the MOAKS score, and postoperative complications, particularly arthrofibrosis.

Patients aged 14-49 years will be enrolled at IRCCS Istituto Ortopedico Rizzoli and Lyon Ortho Clinic. The study includes both a prospective cohort managed according to the Dejour v3.0 algorithm and a retrospective historical control cohort. Follow-up assessments will be performed up to 24 months after surgery.

The study is planned to start on October 1, 2026, with an expected completion date of September 30, 2029. A total sample size of 152 patients (76 per group) is planned.

02

Conditions studied

  • Patellar Instability
  • Trochlear Articular Cartilage Lesions
03

In context

Lead sponsor

Stefano Zaffagnini is the lead sponsor of 16 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted within the facilities of the Orthopedic and Traumatology Clinic II Unit at the IRCCS Istituto Ortopedico Rizzoli and at the Lyon Ortho Clinic. Surgical procedures will be performed at both these institutions.

Patients will be asked to sign an informed consent during the hospital stay and after signing the informed consent will be asked to complete a questionnaire on the preoperative condition.

Clinical follow-up visits will be carried out at the outpatient clinics of the IRCCS Istituto Ortopedico Rizzoli as well as at the Lyon Ortho Clinic.

Eligibility criteria

Inclusion Criteria study group:

  • Patients aged ≥14 years and \<50 years
  • Male and female patients
  • Patients with a clinical history of recurrent objective patellar instability (OPI)
  • Provision of written to participate in the study
  • Patients who performed preoperative imaging studies (MRI) that confirmed the diagnosis and the need for treatment based on the above mentioned criteria (type 3 dysplasia with a bump >5mm)

Exclusion Criteria study group:

  • Patients with established knee osteoarthritis (K-L ≥2)
  • Patients with concomitant ligament injuries (including anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), or collateral ligaments)
  • Patients with a history of prior knee surgery for conditions other than patellar instability
  • Patients who have previously undergone surgical procedures for patellar instability (OPI)
  • Patients with incomplete or inadequate MRI data

Inclusion Criteria control group:

  • Patients aged ≥14 years and \<50 years treated for OPI with another procedure except trochleoplasty in the two reference centres from 2022 to 2024
  • Male and female patients
  • Provision of written informed consent to participate in the study
  • Patients who performed preoperative imaging studies (MRI/CT scan) that confirmed a type 3 dysplasia with a bump >5mm

Exclusion Criteria control group:

  • Patients with concomitant ligament injuries (including anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), or collateral ligaments)
  • Patients with a history of prior knee surgery for conditions other than patellar instability
  • Patients who have had previously undergone surgical procedures for patellar instability (OPI) at the time of the MRI/CT scan
  • Patients with incomplete or inadequate MRI or CT scan data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
152 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case group

    Patients who performed preoperative imaging studies (MRI) that confirmed the diagnosis and the need for treatment based on the above mentioned criteria (type 3 dysplasia with a bump \>5mm). They are treated according to the Dejour v3.0 algorithm, which involves trochleoplasty combined with medial patellofemoral ligament (MPFL) reconstruction.

  • Control group

    The control group includes patients with comparable anatomical characteristics who were previously treated without trochleoplasty.

06

What researchers measure

Primary outcomes

  1. Failure rates

    Defined as reoperation for subsequent atraumatic patellar luxation or persistent instability at 24 months. They will be registered in the CRF during the follow-up visits or during the telephonic contact in case of missing follow-ups. This could also be assessed through the clinical documentation of the patient, in case of missing data.

    Time frame: At 24 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2027; primary completion for Sep 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Jun 2027
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939165
Lead sponsor
Stefano Zaffagnini
Responsible party
Stefano Zaffagnini (Full Professor Medicine and Surgery, University of Bologna, Istituto Ortopedico Rizzoli) — Sponsor-investigator
First posted
Nov 16, 2026
Start date
Jun 2027 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Stefano Zaffagnini
Contact
stefano.zaffagnini@ior.it
0516366075

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion